| Publication |
Investigator(s) |
Lally BE, Geiger AM, Urbanic JJ, Butler JM, Wentworth S, Perry MC, Wilson LD, Horton JK, Detterbeck FC, Miller AA, Thomas CR, Blackstock AW. Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer. 2009;64(2):226-31.
We used the Surveillance, Epidemiology, and End Results (SEER) database to examine the outcomes of patients with limited stage small cell lung cancer (LS-SCLC) over time and to determine if any trends were present with respect to the publication of significant clinical trials. We assembled a cohort of 6271 patients aged 21 years and older with LS-SCLC diagnosed from 1983 to 1998 and followed through 2005. Potential covariates included patient age at diagnosis, sex, race, year of diagnosis, laterality, tumor size, and location (upper lobe, middle lobe, lower lobe. or main bronchus). In multivariate analysis, older age, mate sex, African American race, and main bronchus location were all associated with a statistically significant increase in the mortality hazard. When compared to patients diagnosed in 1983-1987 who did not receive radiotherapy, the hazard for mortality was significantly reduced for patients diagnosed in 1988-1992 regardless of whether they received radiotherapy (HR = 0.59; CI 0.52-0.65: p < 0.0001) or not (HR = 0.67; CI 0.60-0.75; p < 0.0001). Patients who were diagnosed in 1993-1998 and received radiotherapy had similarly improved survival (HR = 0.53; CI 0.47-0.58; p < 0.0001), which was better than patients from the same time era who did not receive radiotherapy (HR = 0.77; CI 0.69-0.85; p < 0.0001). In conclusion, the survival for patients with LS-SCLC has improved over time. Many factors are likely involved, however we believe that part of this improvement was the result of clinical trials which investigated and subsequently defined chemoradiotherapy as the standard of care. In order to continue to improve clinical outcomes, clinical trials investigating new treatment paradigms are needed. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
|
Lally
|
|
|
Lally
|
Morgan PB, Sopka DM, Kathpal M, Haynes JC, Lally BE, Li L. First author research productivity of United States radiation oncology residents: 2002-2007. Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1567-72.
PURPOSE: Participation in investigative research is a required element of radiation oncology residency in the United States. Our purpose was to quantify the first author research productivity of recent U.S. radiation oncology residents during their residency training. METHODS AND MATERIALS: We performed a computer-based search of PubMed and a manual review of the proceedings of the annual meetings of the American Society for Therapeutic Radiology and Oncology to identify all publications and presented abstracts with a radiation oncology resident as the first author between 2002 and 2007. RESULTS: Of 1,098 residents trained at 81 programs, 50% published > or =1 article (range, 0-9), and 53% presented > or =1 abstract (range, 0-3) at an American Society for Therapeutic Radiology and Oncology annual meeting. The national average was 1.01 articles published and 1.09 abstracts presented per resident during 4 years of training. Of 678 articles published, 82% represented original research and 18% were review articles. Residents contributed 15% of all abstracts at American Society for Therapeutic Radiology and Oncology annual meetings, and the resident contribution to orally presented abstracts increased from 12% to 21% during the study period. Individuals training at programs with >6 residents produced roughly twice as many articles and abstracts. Holman Research Pathway residents produced double the national average of articles and abstracts. CONCLUSION: Although variability exists among individuals and among training programs, U.S. radiation oncology residents routinely participate in investigative research suitable for publication or presentation at a scientific meeting. These data provide national research benchmarks that can assist current and future radiation oncology residents and training programs in their self-assessment and research planning.
|
Lally
|
Feigenberg SJ, Sharma N, Yu JQ, Lally B, Borghaei H, Mehra R, Simon G, Scott W, Buyyounouski M, Unger M, Movsas B. Optimal PET response following stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) is closely related to the pre-SBRT maximum standard uptake value. Journal of Thoracic Oncology. 2009 Sep;4(9):S734-S734.
|
Borghaei
Lally
Simon
Mehra
|
Li L, Egleston B, Lally B, Simon G, Turaka A, Mehra R, Borghaei H, Lebenthal A, Walter S, Kuritzky N, Feigenberg SJ. Second primary lung cancers (SPLC) in non small cell lung cancer (NSCLC) survivors: a report on treatment, outcomes, and impact on lung cancer specific mortality. Journal of Thoracic Oncology. 2009 Sep;4(9):S430-S430.
|
Borghaei
Lally
Simon
Mehra
|
|
|
Cohen
Lally
|
|
|
Lally
|
Sanborn RE, Lally BE. Adjuvant therapy for non-small cell lung cancer with mediastinal nodal involvement. Thorac Surg Clin. 2008 Nov;18(4):423-35.
Since the publication of the meta-analysis in 1995 indicating a potential survival benefit with adjuvant cisplatin-based chemotherapy for patients with resected NSCLC, the management of patients with resected NSCLC and N2 disease involvement has evolved dramatically. The delivery of systemic therapy in the postoperative setting remains difficult, however, because tolerance for the toxicities of chemotherapy is reduced by recovery from surgery itself. Even with a proven survival benefit with adjuvant chemotherapy, cure is not guaranteed, and most patients die from relapse of their cancer. Optimization of treatment through the administration of neoadjuvant therapy, application of more modern radiotherapy techniques, and combined-modality therapy with chemoradiation or molecularly targeted agents are areas currently under active investigation. Ideally, the improvement of prediction of which patients harbor micrometastatic disease before undergoing surgical resection and the prediction of which patients would benefit from different systemic therapies may help to improve further the chance of cure for NSCLC while at the same time reducing toxicity.
|
Lally
|